Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042328 · ClinicalTrials.gov registry record · Phase 2
A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients
A Phase 2 study of Neoplasms, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00042328 is a Phase 2 study of Neoplasms that has completed, run by Baylor College of Medicine. The registered enrollment target is 30 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00042328, a Phase 2 study of Neoplasms, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study the pharmacology (how the body handles this drug) of valacyclovir in children receiving treatment for cancer. This study will last approximately 7 days.
Conditions Studied
Interventions
- DRUG Valacyclovir
Study Locations (1)
Texas
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-08 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00042328
The ClinicalTrials.gov registry entry for NCT00042328 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Valacyclovir is the first listed.
NCT00042328 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00042328 about?
NCT00042328 is a clinical study titled "A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients". The purpose of this research is to study the pharmacology (how the body handles this drug) of valacyclovir in children receiving treatment for cancer. This study will last approximately 7 days.
What is the current status of trial NCT00042328?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2001-08. Estimated completion is 2005-05.
What conditions does trial NCT00042328 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT00042328?
The interventions under investigation include: Valacyclovir (DRUG).
Who is sponsoring clinical trial NCT00042328?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00042328 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
RECRUITING · Phase 2
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
-
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
RECRUITING · Phase 2
-
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.